Low doses of transdermal buprenorphine in opioid-naive patients with cancer pain: A 4-week, nonrandomized, open-label, uncontrolled observational study

Clinical Therapeutics

Volumn 31, Issue 10, 2009, Pages 2134-2138

  Mercadante, Sebastiano ^a,b   Porzio, Gianpiero ^c   Ferrera, Patrizia ^a   Aielli, Federica ^c   Verna, Lucilla ^c   Tirelli, Walter ^d   Villari, Patrizia ^a   Casuccio, Alessandra ^b  

^a LA MADDALENA CANCER CENTER   (Italy)

^b UNIVERSITY OF PALERMO   (Italy)

^c UNIVERSITY OF L'AQUILA   (Italy)

^d REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

buprenorphine; cancer pain; morphine; opioids

Indexed keywords

BUPRENORPHINE; MORPHINE;

ADVANCED CANCER; AGED; ARTICLE; CANCER PAIN; CLINICAL ARTICLE; CLINICAL TRIAL; CONFUSION; CONSTIPATION; DROWSINESS; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MONITORING; DRUG RESPONSE; DRUG TOLERABILITY; FEMALE; HUMAN; LOW DRUG DOSE; MALE; NAUSEA AND VOMITING; OBSERVATIONAL STUDY; PAIN ASSESSMENT; QUALITY OF LIFE; TREATMENT DURATION; XEROSTOMIA;

ADMINISTRATION, CUTANEOUS; AGED; ANALGESICS, OPIOID; BUPRENORPHINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PAIN MEASUREMENT; PAIN, INTRACTABLE; QUALITY OF LIFE;

EID: 71549165466     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2009.10.013     Document Type: Article

References (13)

1. Cancer pain relief and palliative care. Report of a WHO Expert Committee. World Health Organ Tech Rep Ser. 804 (1990) 1-75
2. Jadad A.R., and Browman G.P. The WHO analgesic ladder for cancer pain management. Stepping up the quality of its evaluation. JAMA 274 (1995) 1870-1873
3. Mercadante S., Porzio G., Ferrera P., et al. Low morphine doses in opioid-naive cancer patients with pain. J Pain Symptom Manage 31 (2006) 242-247
4. De Conno F., Ripamonti C., Fagnoni E., et al., MERITO Study Group. The MERITO Study: A multicentre trial of the analgesic effect and tolerability of normal-release oral morphine during 'titration phase' in patients with cancer pain. Palliat Med. 22 (2008) 214-221
5. Koizumi W., Toma H., Watanabe K., et al. Efficacy and tolerability of cancer pain management with controlled-release oxycodone tablets in opioid-naive cancer pain patients, starting with 5 mg tablets. Jpn J Clin Oncol 34 (2004) 608-614
6. Sittl R., Griessinger N., and Likar R. Analgesic efficacy and tolerability of transdermal buprenorphine in patients with inadequately controlled chronic pain related to cancer and other disorders: A multicenter, randomized, double-blind, placebo-controlled trial. Clin Ther 23 (2003) 150-168
7. Addington-Hall J.M., MacDonald L.D., and Anderson H.R. Can the Spitzer Quality of Life Index help to reduce prognostic uncertainty in terminal care?. Br J Cancer 62 (1990) 695-699
8. Wassertheil-Smoller S. Mostly about statistics. Biostatistics and Epidemiology: A Primer for Health Professionals (1995), Springer-Verlag, New York, NY 27-84
9. Mercadante S., Dardanoni G., Salvaggio L., et al. Monitoring of opioid therapy in advanced cancer pain patients. J Pain Symptom Manage 13 (1997) 204-212
10. Mercadante S., and Bruera E. Opioid switching: A systematic and critical review. Cancer Treat Rev. 32 (2006) 304-315
11. Hanks G.W., De Conno F., Cherny N., et al., Expert Working Group of the Research Network of the European Association for Palliative Care. Morphine and alternative opioids in cancer pain: The EAPC recommendations. Br J Cancer 84 (2001) 587-593
12. Mercadante S. Opioid titration in cancer pain: A critical review. Eur J Pain 11 (2007) 823-830
13. Maltoni M., Scarpi E., Modonesi C., et al. A validation study of the WHO analgesic ladder: A two-step vs three-step strategy. Support Care Cancer 13 (2005) 888-894